Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

NCT06437353 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Paclitaxel

Sponsor

Anhui Provincial Cancer Hospital

Collaborators

[object Object]